Ktel 40 Tablet contains Telmisartan 40 mg, an angiotensin II receptor antagonist primarily used for the management of hypertension. By selectively blocking the binding of angiotensin II to the AT1 receptor, Telmisartan effectively reduces vasoconstriction and aldosterone secretion, leading to decreased blood pressure and improved cardiovascular outcomes. Ktel 40 is indicated for the treatment of essential hypertension to lower the risk of stroke, myocardial infarction, and other cardiovascular events. It may also be prescribed for patients with left ventricular hypertrophy or those at high cardiovascular risk who are intolerant to ACE inhibitors. The tablet is administered orally, typically once daily, with or without food, ensuring convenient dosing and improved patient compliance. Common adverse effects include dizziness, headache, and fatigue, though it is generally well tolerated. Caution is advised in patients with renal impairment, hepatic dysfunction, or electrolyte imbalances, and it is contraindicated during pregnancy due to potential fetal toxicity. Regular monitoring of blood pressure, renal function, and serum electrolytes is recommended during therapy. Ktel 40 Tablet should be used under medical supervision to optimize therapeutic benefits while minimizing risks.